GastroEsophageal Cancer New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer Ulas D. Bayraktar, MD 2023-08-20
Non-Small Cell Lung Cancer New Indication: Pembrolizumab for Early-Stage NSCLC Ulas D. Bayraktar, MD 2023-08-20
Non-Small Cell Lung Cancer New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC Ulas D. Bayraktar, MD 2023-08-20
Uterine Cancer New Protocol: Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma Ulas D. Bayraktar, MD 2023-08-20
Renal Cell Carcinoma New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC Ulas D. Bayraktar, MD 2023-08-20
Prostate Cancer New Indication: Talazoparib and Enzalutamide in Metastatic CRPC Ulas D. Bayraktar, MD 2023-06-24
Breast Cancer New Indication: Adjuvant Ribociclib and Endocrine Therapy in Breast Cancer Ulas D. Bayraktar, MD 2023-06-24
Ovarian Cancer New Drug: Mirvetuximab Soravtansine in Advanced Ovarian Cancer Ulas D. Bayraktar, MD 2023-06-24
Soft Tissue Sarcoma New Protocol: Nivolumab and Trabectedin in Advanced Soft Tissue Sarcoma Ulas D. Bayraktar, MD 2023-06-24
Hepatocellular Carcinoma New Indication: Adjuvant Atezolizumab – Bevacizumab in HCC Ulas D. Bayraktar, MD 2023-06-24
